Cargando…
Antileishmanial activity of 5-nitroindazole derivatives
BACKGROUND: Currently, there is no safe and effective vaccine against leishmaniasis and existing therapies are inadequate due to high toxicity, cost and decreased efficacy caused by the emergence of resistant parasite strains. Some indazole derivatives have shown in vitro and in vivo activity agains...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10617274/ https://www.ncbi.nlm.nih.gov/pubmed/37915499 http://dx.doi.org/10.1177/20499361231208294 |
_version_ | 1785129574433030144 |
---|---|
author | Mollineda-Diogo, Niurka Chaviano-Montes de Oca, Claudia Sissely Sifontes-Rodríguez, Sergio Espinosa-Buitrago, Teresa Monzote-Fidalgo, Lianet Meneses-Marcel, Alfredo Morales-Helguera, Aliuska Perez-Castillo, Yunierkis Arán-Redó, Vicente |
author_facet | Mollineda-Diogo, Niurka Chaviano-Montes de Oca, Claudia Sissely Sifontes-Rodríguez, Sergio Espinosa-Buitrago, Teresa Monzote-Fidalgo, Lianet Meneses-Marcel, Alfredo Morales-Helguera, Aliuska Perez-Castillo, Yunierkis Arán-Redó, Vicente |
author_sort | Mollineda-Diogo, Niurka |
collection | PubMed |
description | BACKGROUND: Currently, there is no safe and effective vaccine against leishmaniasis and existing therapies are inadequate due to high toxicity, cost and decreased efficacy caused by the emergence of resistant parasite strains. Some indazole derivatives have shown in vitro and in vivo activity against Trichomonas vaginalis and Trypanosoma cruzi. On that basis, 20 indazole derivatives were tested in vitro against Leishmania amazonensis. OBJECTIVE: To evaluate the in vitro activity of twenty 2-benzyl-5-nitroindazolin-3-one derivatives against L. amazonensis. DESIGN: For the selection of promising compounds, it is necessary to evaluate the indicators for in vitro activity. For this aim, a battery of studies for antileishmanial activity and cytotoxicity were implemented. These results enabled the determination of the substituents in the indazole derivatives responsible for activity and selectivity, through the analysis of the structure–activity relationship (SAR). METHODS: In vitro cytotoxicity against mouse peritoneal macrophages and growth inhibitory activity in promastigotes were evaluated for 20 compounds. Compounds that showed adequate selectivity were tested against intracellular amastigotes. The SAR from the results in promastigotes was represented using the SARANEA software. RESULTS: Eight compounds showed selectivity index >10% and 50% inhibitory concentration <1 µM against the promastigote stage. Against intracellular amastigotes, four were as active as Amphotericin B. The best results were obtained for 2-(benzyl-2,3-dihydro-5-nitro-3-oxoindazol-1-yl) ethyl acetate, with 50% inhibitory concentration of 0.46 ± 0.01 µM against amastigotes and a selectivity index of 875. The SAR study showed the positive effect on the selectivity of the hydrophilic fragments substituted in position 1 of 2-benzyl-5- nitroindazolin-3-one, which played a key role in improving the selectivity profile of this series of compounds. CONCLUSION: 2-bencyl-5-nitroindazolin-3-one derivatives showed selective and potent in vitro activity, supporting further investigations on this family of compounds as potential antileishmanial hits. |
format | Online Article Text |
id | pubmed-10617274 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-106172742023-11-01 Antileishmanial activity of 5-nitroindazole derivatives Mollineda-Diogo, Niurka Chaviano-Montes de Oca, Claudia Sissely Sifontes-Rodríguez, Sergio Espinosa-Buitrago, Teresa Monzote-Fidalgo, Lianet Meneses-Marcel, Alfredo Morales-Helguera, Aliuska Perez-Castillo, Yunierkis Arán-Redó, Vicente Ther Adv Infect Dis Original Research BACKGROUND: Currently, there is no safe and effective vaccine against leishmaniasis and existing therapies are inadequate due to high toxicity, cost and decreased efficacy caused by the emergence of resistant parasite strains. Some indazole derivatives have shown in vitro and in vivo activity against Trichomonas vaginalis and Trypanosoma cruzi. On that basis, 20 indazole derivatives were tested in vitro against Leishmania amazonensis. OBJECTIVE: To evaluate the in vitro activity of twenty 2-benzyl-5-nitroindazolin-3-one derivatives against L. amazonensis. DESIGN: For the selection of promising compounds, it is necessary to evaluate the indicators for in vitro activity. For this aim, a battery of studies for antileishmanial activity and cytotoxicity were implemented. These results enabled the determination of the substituents in the indazole derivatives responsible for activity and selectivity, through the analysis of the structure–activity relationship (SAR). METHODS: In vitro cytotoxicity against mouse peritoneal macrophages and growth inhibitory activity in promastigotes were evaluated for 20 compounds. Compounds that showed adequate selectivity were tested against intracellular amastigotes. The SAR from the results in promastigotes was represented using the SARANEA software. RESULTS: Eight compounds showed selectivity index >10% and 50% inhibitory concentration <1 µM against the promastigote stage. Against intracellular amastigotes, four were as active as Amphotericin B. The best results were obtained for 2-(benzyl-2,3-dihydro-5-nitro-3-oxoindazol-1-yl) ethyl acetate, with 50% inhibitory concentration of 0.46 ± 0.01 µM against amastigotes and a selectivity index of 875. The SAR study showed the positive effect on the selectivity of the hydrophilic fragments substituted in position 1 of 2-benzyl-5- nitroindazolin-3-one, which played a key role in improving the selectivity profile of this series of compounds. CONCLUSION: 2-bencyl-5-nitroindazolin-3-one derivatives showed selective and potent in vitro activity, supporting further investigations on this family of compounds as potential antileishmanial hits. SAGE Publications 2023-10-30 /pmc/articles/PMC10617274/ /pubmed/37915499 http://dx.doi.org/10.1177/20499361231208294 Text en © The Author(s), 2023 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Original Research Mollineda-Diogo, Niurka Chaviano-Montes de Oca, Claudia Sissely Sifontes-Rodríguez, Sergio Espinosa-Buitrago, Teresa Monzote-Fidalgo, Lianet Meneses-Marcel, Alfredo Morales-Helguera, Aliuska Perez-Castillo, Yunierkis Arán-Redó, Vicente Antileishmanial activity of 5-nitroindazole derivatives |
title | Antileishmanial activity of 5-nitroindazole derivatives |
title_full | Antileishmanial activity of 5-nitroindazole derivatives |
title_fullStr | Antileishmanial activity of 5-nitroindazole derivatives |
title_full_unstemmed | Antileishmanial activity of 5-nitroindazole derivatives |
title_short | Antileishmanial activity of 5-nitroindazole derivatives |
title_sort | antileishmanial activity of 5-nitroindazole derivatives |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10617274/ https://www.ncbi.nlm.nih.gov/pubmed/37915499 http://dx.doi.org/10.1177/20499361231208294 |
work_keys_str_mv | AT mollinedadiogoniurka antileishmanialactivityof5nitroindazolederivatives AT chavianomontesdeocaclaudiasissely antileishmanialactivityof5nitroindazolederivatives AT sifontesrodriguezsergio antileishmanialactivityof5nitroindazolederivatives AT espinosabuitragoteresa antileishmanialactivityof5nitroindazolederivatives AT monzotefidalgolianet antileishmanialactivityof5nitroindazolederivatives AT menesesmarcelalfredo antileishmanialactivityof5nitroindazolederivatives AT moraleshelgueraaliuska antileishmanialactivityof5nitroindazolederivatives AT perezcastilloyunierkis antileishmanialactivityof5nitroindazolederivatives AT aranredovicente antileishmanialactivityof5nitroindazolederivatives |